Cadila Healthcare soars after USFDA approval for Perphenazine tablets

Cadila Healthcare jumped 13.05% to Rs 310.95 after the company said it received final approval from the US drug regulator to market Perphenazine tablets in multiple strengths.

This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults.

The drug will be manufactured at the group's formulation manufacturing facility at Baddi, Himachal Pradesh.

The group now has 284 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. The announcement was made during market hours today, 7 April 2020.

The pharma major on Thursday, 2 April 2020, received the final approval from United States Food and Drug Administration (USFDA) to market Lamotrigine extended-release tablets USP in multiple strengths of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg. The medication is indicated for treating certain types of seizures. It will be manufactured at the group manufacturing facility at SEZ, Ahmedabad, Gujarat.

On a consolidated basis, the drug maker's net profit fell 26.54% to Rs 375.18 crore on a 0.52% increase in net sales to Rs 3,534.50 crore in Q3 December 2019 Q3 December 2018.

Cadila Healthcare is a pharmaceutical company based in India.

Powered by Capital Market - Live News